2025 Mavacamten Price Trend Forecast

Since mavacamten (mavacamten) entered the international market, it has attracted much attention for its new myocardial regulation target mechanism. It is mainly used to treat obstructive hypertrophic cardiomyopathy (HCM) by reducing myocardial contractility and improving outflow tract pressure gradient to improve patients' activity tolerance and quality of life. Unlike traditional treatments that rely more on beta-blockers or surgical intervention, Mavakate It provides patients with a drug treatment path that can be maintained for a long time and can be dynamically adjusted according to cardiac function status. It is suitable for people who have insufficient response to traditional drugs or are not suitable for surgery.

As drugs are launched in China and included in medical insurance, the accessibility for domestic patients has significantly improved. The out-of-pocket ratio after medical insurance has been significantly reduced, making it one of the few targeted oral drugs in the field of cardiomyopathy in China that can be afforded in the long term. Common strengths include 2.5mg, 5mg, 10mg and 15mg, which are suitable for dose adjustment strategies at different stages. Due to the short time to market, domestic prices are still at a stable stage, but medical insurance coverage makes the cost significantly lower than in overseas markets, which is likely to promote the expansion of its user population in the future.

In the international market, there is a big price difference between the American version and the European version. The price of a single box of the American version 2.5mg can reach about 60,000 yuan, while the European version sells for about 20,000 yuan. This is mainly affected by the pricing system, medical insurance system and supply channels. In overseas pharmaceutical markets, innovative drugs for heart disease are usually priced higher, and the emergence of generic versions often drives down overall prices. Some overseas countries have seen a trend of gradually lowering prices, especially after the local launch of generic versions, the price gradient has rapidly increased. Currently, each box of generic drugs in some channels is about RMB 1,500.

The price trend in the future is likely to be polarized: in China, due to medical insurance coverage and centralized procurement policies, prices have generally stabilized or even declined slowly; while overseas original drug prices may continue to remain high until generic drugs become more popular.

References: https://bnf.nice.org.uk/drugs/mavacamten/